Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells

Ou, Hanlin; Cheng, Tangjian; Zhang, Yumin; Liu, Jinjian; Ding, Yuxun; Zhen, Jingru; Shen, Wei Feng; Xu, Ying-Jin; Yang, Wenzeng; Niu, Pei; Liu, Jianfeng; An, Yingli; Yang, Liu; Shi, Linqi

doi:10.1016/j.actbio.2017.10.034

Cited by 137 publications

(84 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles are able to enhance the therapeutic efficacy of anticancer drugs [7], owing to their ability to increase the drug concentration in tumor cells through enhancing the drug circulation time. Also, nanoparticles have the capability of delivering drugs to their target sites in an in vivo environment, and thereby they can inhibit the drugs' side effects on normal cells [6,45,46].…”

Section: Cytotoxicity Studymentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder cancer (BC). Cispt was loaded into liposomes using reverse-phase evaporation method, and the formulations were characterized using dynamic light scattering, scanning electron microscopy, dialysis membrane, and Fourier-transform infrared spectroscopy (FTIR) methods. The results showed that the particles were formed in spherical monodispersed shapes with a nanoscale size (221–274 nm) and controlled drug release profile. The cytotoxicity effects of LCispt and PLCispt were assessed in an in vitro environment, and the results demonstrated that PLCispt caused a 2.4- and 1.9-fold increase in the cytotoxicity effects of Cispt after 24 and 48 h, respectively. The therapeutic and toxicity effects of the formulations were also assessed on BC-bearing rats. The results showed that PLCispt caused a 4.8-fold increase in the drug efficacy (tumor volume of 11 ± 0.5 and 2.3 ± 0.1 mm3 in Cispt and PLCispt receiver rats, respectively) and a 3.3-fold decrease in the toxicity effects of the drug (bodyweight gains of 3% and 10% in Cispt and PLCispt receiver rats, respectively). The results of toxicity were also confirmed by histopathological studies. Overall, this study suggests that the PEGylation of LCispt is a promising approach to achieve a nanoformulation with enhanced anticancer effects and reduced toxicity compared to Cispt for the treatment of BC.

show abstract

Section: Cytotoxicity Studymentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Positing that zwitterionic materials have been found to be superior to PEG for overcoming undesirable immune responses after administration, Ou et al designed poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC)/poly(β-amino ester) (PAE) modified poly(ε-caprolactone) (PCL) micelles to form a mixed-shell micelles (MSMs) (Figure 8b) in order to evaluate their in vivo circulation and determine anti-polymer antibody production [80]. Single PEG-PCL micelles (PEGSMs) and single PMPC-PCL micelles (PMPCSMs) were utilized as controls.…”

Section: Zwitterionic Polymersmentioning

confidence: 99%

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

et al. 2020

View full text Add to dashboard Cite

Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.

show abstract

“…Nanoparticles play an important role in the treatment of cancers as they can (i) increase drug concentration in cancerous cells, due to a prolonged circulation which helps nanoparticles to meet their targets, and (ii) prevent drug toxicity in normal cells, due to targeting capacity in an in vivo environment [52,53]. Various studies showed that drug encapsulation into nanocarriers increased their cytotoxicity effects on the cancerous cells [13,15,16].…”

Section: In Vitro Cytotoxicity Effectsmentioning

confidence: 99%

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

et al. 2020

View full text Add to dashboard Cite

This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats.

show abstract

Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells

Cited by 137 publications

References 63 publications

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

Contact Info

Product

Resources

About